Investors sort through hundreds of startups every year, and the path from first glance to funding decision runs through two distinct phases: screening and evaluation. Each phase calls for different market forecast data. Getting the data priorities wrong at either stage wastes time and money. In this guide, BCC Research breaks down which data inputs drive confident decisions at each step of early-stage due diligence.
You will learn what distinguishes screening from evaluation, which market research inputs serve each phase, and how to avoid common traps that slow deal flow. By the end, you will know exactly which forecast data to prioritize whether you are filtering 500 pitch decks or digging into a single opportunity.
Startup screening is the first filter in early-stage investing. At this stage, you review pitch materials, check for sector fit, and determine whether the opportunity deserves more time. Most venture firms screen hundreds or thousands of startups annually, advancing only a fraction to deeper diligence.
Screening decisions happen fast. A typical screening session lasts minutes, not hours. The goal is elimination, not selection. You want to quickly rule out deals that do not match your fund's thesis, timeline, or risk appetite.
Pros:
Cons:
Startup evaluation is the deep dive. After a deal passes screening, you invest significant time and resources to understand the company's market position, competitive moat, and growth trajectory. Evaluation-stage work often takes weeks and involves primary research, financial modeling, and reference calls.
At this phase, surface-level market data is insufficient. You need granular segment forecasts, market share analysis, and regulatory landscape reviews. The stakes are higher because evaluation precedes term sheets and capital deployment.
Pros:
Cons:
During screening, you rely on top-down TAM figures to gauge whether the opportunity operates at venture scale. A quick check against published market sizes tells you if the sector has room for outsized returns. Most VCs look for TAM above one billion dollars as a baseline.
Evaluation shifts to bottom-up sizing. You break the market into segments, validate assumptions against company filings, and test founder claims with independent data. BCC Research reports include both top-down totals and segment-level breakdowns so you can move between stages without switching sources.
Screening calls for headline growth rates. A 15% CAGR tells you the sector has tailwinds. You do not need quarterly projections or regional splits at this stage. Directional confidence is the goal.
Evaluation requires five-year forecasts broken down by region, application, and end market. These granular projections anchor your financial model and inform revenue assumptions. BCC Research delivers this level of detail across life sciences, technology, advanced materials, and dozens of other sectors.
At screening, speed often trumps precision. Founders frequently cite third-party reports; your job is to confirm the source is reputable. A brief credibility check can prevent reliance on inflated figures that collapse under scrutiny later.
Evaluation demands higher standards. You triangulate forecasts from multiple sources, verify methodologies, and identify potential biases. BCC Research maintains strict separation between research and revenue, with no pay-to-play model influencing findings. This independence supports citations that survive investor diligence.
Screening typically involves a quick count of existing players. Are there dominant incumbents? Is the market fragmented? You need enough context to gauge whether a new entrant can capture share.
Evaluation expands this into full competitive analysis. Market share data, company profiles, recent funding rounds, and patent activity all inform your thesis. BCC Research reports include detailed company profiles with financials, key developments, and strategic positioning.
For screening, a basic scan for regulatory red flags is usually sufficient. Does the sector face pending legislation that could disrupt business models? Are there obvious ESG concerns that conflict with your fund mandate?
Evaluation requires deeper regulatory mapping. You need to understand compliance requirements, approval timelines, and policy trends that could affect time-to-market. BCC Research life sciences reports include patent reviews and regulatory landscape analysis for pharmaceutical, biotechnology, and medical device markets.
| Data Requirement | BCC Research | Generic Report Providers | DIY Research |
|---|---|---|---|
| Five-Year Forecasts | ✓ | ✓ | ✗ |
| Segment-Level Breakdowns | ✓ | Limited | ✗ |
| Company Profiles with Financials | ✓ | Limited | ✗ |
| Patent and Regulatory Analysis | ✓ | ✗ | ✗ |
| Independent Analyst Commentary | ✓ | ✗ | ✗ |
| Custom Consulting Available | ✓ | Limited | N/A |
Investment professionals need data they can trust when capital is on the line. BCC Research has supported strategic decision-making for more than 50 years, earning the confidence of Fortune 500 companies and global innovators. The firm maintains over 50 in-house analysts with deep expertise across biotechnology, advanced materials, energy, and high technology.
Unlike providers that rely primarily on web-scraped data, BCC Research combines primary and secondary research methodologies. This mixed-method approach delivers qualitative insights alongside quantitative forecasts. When founders cite market sizes in pitch decks, BCC Research data gives you the independent verification you need.
For investors who require tailored analysis, BCC Research custom consulting builds reports scoped to your exact thesis. You choose the market segments, regions, and target companies. The result is proprietary intelligence that strengthens both screening efficiency and evaluation depth. Contact the team to discuss your next deal.
Screening is the quick filter that determines if an opportunity deserves more time. Evaluation is the in-depth analysis that informs investment decisions. BCC Research supports both stages with executive summaries for rapid scanning and detailed forecasts for deep diligence.
Top-down TAM figures, sector growth rates, and competitive density are the primary inputs. You need enough data to confirm the opportunity aligns with your fund's thesis without investing hours in research. A five-minute check against a trusted source like BCC Research saves significant time downstream.
Evaluation requires bottom-up market sizing, segment-level forecasts, regulatory mapping, and company-level competitive analysis. This work typically takes weeks and informs your valuation model and term sheet negotiations.
Independent research validates founder claims, reduces reliance on internally generated figures, and gives investment committee presentations a defensible basis. BCC Research reports are frequently cited in board materials and investor updates because the methodology is transparent and the data is analyst-verified.
BCC Research offers over 5,000 reports with five-year forecasts, market share data, and company profiles. Membership plans unlock unlimited access to specific categories, enabling your team to pull relevant data without per-report costs. Custom consulting delivers tailored analysis for specific thesis requirements.
BCC Research covers life sciences, biotechnology, advanced materials, chemicals, information technology, energy, environment, and manufacturing. The library spans both emerging and established markets across global regions.